Search

Your search keyword '"Verzoni, E."' showing total 374 results
Start Over Author "Verzoni, E."
374 results on '"Verzoni, E."'

1. Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

Author

Choueiri, T.K., Kuzel, T.M., Tykodi, S.S., Verzoni, E., Kluger, H., Nair, S., Perets, R., George, S., Gurney, H., Pachynski, R.K., Folefac, E., Castonguay, V., Lee, C.-H., Vaishampayan, U., Miller, W.H., Jr., Bhagavatheeswaran, P., Wang, Y., Gupta, S., DeSilva, H., Lee, C.-W., Escudier, B., and Motzer, R.J. more...

Published
2024
Full Text
View/download PDF

2. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

Author

Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, and Procopio G

Subjects
rcc, post-operative, tkis, immunotherapy, clear cell, pembrolizumab., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Achille Bottiglieri, Pierangela Sepe, Marco Stellato, Chiara Pircher, Giuseppe Fotia, Alberto Giovanni Leone, Valentina Guadalupi, Melanie Claps, Patrizia Giannatempo, Elena Verzoni, Giuseppe Procopio Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyCorrespondence: Achille Bottiglieri, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, Milan, Italy, Tel +39 02 2390 2751, Email achille.bottiglieri@istitutotumori.mi.itAbstract: Renal cell carcinoma (RCC) is the fourteenth most common cancer worldwide. In about 55% of cases, it is diagnosed at a localised and/or locally advanced stage and therefore amenable to a curative approach. Although nephrectomy still represents the cornerstone of non-metastatic RCC (nmRCC) treatment, a relapse is observed in about 25– 30% of patients undergoing curative surgery. Prognosis is drastically influenced by lymph nodal involvement. After the first disappointing results with a cytokine-based strategy, tyrosine kinase inhibitors (TKIs) were tested as adjuvant agents. Despite their efficacy in the metastatic setting, results in terms of disease-free survival (DFS) are not unequivocal and the overall survival (OS) benefit has not been demonstrated. Moreover, their toxicity profile induced a remarkable percentage of patients to discontinue the treatment. On the contrary, the KEYNOTE-564 trial showed the benefit of adjuvant pembrolizumab compared with placebo in terms of DFS with promising results in term of OS. Patients included were at intermediate or high risk of relapse, or patients with no evidence of disease after metastasectomy (M1 NED). The updated analysis presented at the American Society of Clinical Oncology Genito-Urinary (ASCO GU) 2022 confirmed the benefit of pembrolizumab versus placebo over time, although OS data are still immature. A longer follow-up and the several ongoing trials with immune checkpoint inhibitors (ICIs) will provide further data about adjuvant immuno-oncology (IO). Furthermore, the patients’ selection based on clinical or biological features will be crucial in order to identify who benefits most from treatments.Keywords: RCC, post-operative, TKIs, immunotherapy, clear cell, pembrolizumab more...

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results

3. Does multiparametric (mp) MRI and MRI-informed biopsy improve risk allocation of men at inclusion in active surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial

Author

Marenghi, C., primary, Badenchini, F., additional, Rancati, T., additional, Avuzzi, B., additional, Messina, A., additional, Casale, A., additional, Catanzaro, M.A., additional, Claps, M., additional, Casbarra, A., additional, Noris Chiorda, B., additional, Guadalupi, V., additional, Stellato, M., additional, Nazzani, S., additional, Stagni, S., additional, Cattaneo, L., additional, Macchi, A., additional, Villa, S., additional, Torelli, T., additional, Verzoni, E., additional, Tesone, A., additional, Procopio, G., additional, and Nicolai, N., additional more...

Published
2024
Full Text
View/download PDF

4. Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years’ experience

Author

Marenghi, C., primary, Badenchini, F., additional, Avuzzi, B., additional, Catanzaro, M.A., additional, Claps, M., additional, Casbarra, A., additional, Noris Chiorda, B., additional, Guadalupi, V., additional, Stellato, M., additional, Nazzani, S., additional, Stagn, S., additional, Cattaneo, L., additional, Casale, A., additional, Messina, A., additional, Villa, S., additional, Macchi, A., additional, Torelli, T., additional, Tesone, A., additional, Verzoni, E., additional, Procopio, G., additional, Rancati, T., additional, and Nicolai, N., additional more...

Published
2024
Full Text
View/download PDF

5. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial

Author

Sgambelluri, F., primary, Giannatempo, P., additional, Stellato, M., additional, Guadalupi, V., additional, Raggi, D., additional, Bottiglieri, A., additional, Claps, M., additional, Ferrari Bravo, W., additional, Oldani, S., additional, Zimatore, M., additional, Calareso, G., additional, Alessi, A., additional, Cattaneo, L., additional, Verzoni, E., additional, De Braud, F.G.M., additional, Procopio, G., additional, Necchi, A., additional, Anichini, A., additional, and Mortarini, R., additional more...

Published
2023
Full Text
View/download PDF

6. Grade reclassification during active surveillance in low risk prostate cancer men selected with an MRI-informed biopsy

Author

Marenghi, C., primary, Badenchini, F., additional, Avuzzi, B., additional, Catanzaro, M.A., additional, Claps, M., additional, Casbarra, A., additional, Noris Chiorda, B., additional, Guadalupi, V., additional, Stellato, M., additional, Nazzani, S., additional, Stagni, S., additional, Cattaneo, L., additional, Casale, A., additional, Messina, A., additional, Villa, S., additional, Macchi, A., additional, Torelli, T., additional, Verzoni, E., additional, Procopio, G., additional, Rancati, T., additional, and Nicolai, N., additional more...

Published
2023
Full Text
View/download PDF

7. 2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

Author

Bottiglieri, A., primary, Ferrari Bravo, W., additional, Rametta, A., additional, Provenzano, L., additional, Raggi, D., additional, Marandino, L., additional, Farè, E., additional, Longo, V., additional, Guadalupi, V., additional, Stellato, M., additional, Verzoni, E., additional, Sepe, P., additional, Claps, M., additional, Calareso, G., additional, Alessi, A., additional, Cattaneo, L., additional, Colecchia, M., additional, Procopio, G., additional, Necchi, A., additional, and Giannatempo, P., additional more...

Published
2023
Full Text
View/download PDF

9. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours

Author

Celsa, C., Cabibbo, G., Fulgenzi, C. AM, Scheiner, B., d'Alessio, A., Manfredi, G. F, Nishida, N., Ang, C., Marron, T.U., Saeed, A., Wietharn, B., Pinter, M., Cheon, J., Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, S., Gampa, A., Pillai, A., Vivaldi, C., Salani, F., Masi, G., Roehlen, N., Thimme, R., Vogel, A., Schönlein, M., von Felden, J., Schulze, K., Wege, H., Galle, P.R., Kudo, M., Rimassa, L., Singal, A.G., Tomb, P. El, Ulahannan, S., Parisi, A., Chon, H. Jae, Hsu, Wei-Fan, Stefanini, B., Verzoni, E., Giusti, R., Veccia, A., Catino, A., Aprile, G., Guglielmini, P.F., Di Napoli, M., Ermacora, P., Antonuzzo, L., Rossi, E., Verderame, F., Zustovich, F., Ficorella, C., Di Pietro, F.R., Battelli, N., Negrini, G., Grossi, F., Bordonaro, R., Pipitone, S., Banzi, M., Ricciardi, S., Laera, L., Russo, A., De Giorgi, U., Cavanna, L., Sorarù, M., Montesarchio, V., Bordi, P., Brunetti, L., Pinto, C., Bersanelli, M., Cortellini, A., Cammà, C., and Pinato, D.J. more...

Published
2024
Full Text
View/download PDF

10. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

Author

Grassi P, Verzoni E, Ratta R, Mennitto A, de Braud F, and Procopio G

Subjects
cabozantinib, XL-184, metastatic renal cell carcinoma, VEGF-inhibitor, C-Met, targeted therapy, Therapeutics. Pharmacology, RM1-950
Abstract

Paolo Grassi, Elena Verzoni, Raffaele Ratta, Alessia Mennitto, Filippo de Braud, Giuseppe Procopio Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto nazionale Tumori, Milan, Italy Abstract: The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit of these systemic treatments. Recently, a better understanding of the involvement of MET and its ligand HGF in many biological processes made this signaling pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free survival and overall survival when compared to everolimus in mRCC patients who had progressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib within the current treatment landscape for mRCC. Keywords: cabozantinib, XL-184, metastatic renal cell carcinoma, VEGF-inhibitor, c-Met, targeted therapy more...

Published
2016

12. Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Author

Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, and Procopio G

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Elena Verzoni, Paolo Grassi, Isabella Testa, Roberto Iacovelli, Pamela Biondani, Enrico Garanzini , Filippo De Braud, Giuseppe ProcopioDepartment of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyAbstract: Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and is currently being developed for the treatment of various malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, with minimal adverse reactions and enhanced safety. In a large Phase III study of previously treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free survival than sorafenib with an acceptable safety profile and good quality of life. This review focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting needs to be evaluated in further clinical trials.Keywords: axitinib, renal cell carcinoma, vascular endothelial growth factor receptor, angiogenesis more...

Published
2014

13. 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)

Author

Stellato, M., primary, Buti, S., additional, Maruzzo, M., additional, Bersanelli, M., additional, Ermacora, P., additional, Maiorano, B.A., additional, Prati, V., additional, De Giorgi, U.F.F., additional, Pierantoni, F., additional, Malgeri, A., additional, Mennitto, A., additional, Cavo, A., additional, Vitale, M.G., additional, Santoni, M., additional, Carella, C., additional, Procopio, G., additional, Verzoni, E., additional, and Santini, D., additional more...

Published
2022
Full Text
View/download PDF

14. 1470P Transcriptomic signature and immune infiltrate in metastatic collecting duct renal cell carcinoma patients treated with first-line cabozantinib: Results of exploratory endpoints from BONSAI trial (Meeturo 2)

Author

Verzoni, E., primary, Todoerti, K., additional, Rivoltini, L., additional, Huber, V., additional, Rodolfo, M., additional, Agnelli, L., additional, Devecchi, A., additional, Busico, A., additional, Perrone, F., additional, Centonze, G., additional, De Cecco, L., additional, Claps, M., additional, Guadalupi, V., additional, Stellato, M., additional, Giannatempo, P., additional, De Braud, F.G.M., additional, Procopio, G., additional, and Sepe, P., additional more...

Published
2022
Full Text
View/download PDF

15. LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)

Author

Rini, B.I., Suarez Rodriguez, C., Albiges, L., Jalkanen, K., De Velasco Oria, G.A., Burotto, M., Ghatalia, P., Iacovelli, R., Lam, E.T., Verzoni, E., Gumus, M., Stadler, W., Kollmannsberger, C.K., Melichar, B., Venugopal, B., Lin, J., Perini, R., Vickery, D., Choueiri, T.K., and Powles, T.B. more...

Published
2024
Full Text
View/download PDF

17. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy

Author

Terbuch, A, Posch, F, Bauernhofer, T, Jost, PJ, Partl, R, Stranzl-Lawatsch, H, Baciarello, G, Fizazi, K, Giannatempo, P, Verzoni, E, Sweeney, C, Ravi, P, Tran, B, Basso, U, White, J, Vincenzi, B, Oing, C, Cutuli, HJ, Dieckmann, KP, Gamulin, M, Chovanec, M, Fankhauser, CD, Heidenreich, A, Mohamad, O, Thibault, C, Fischer, S, Gillessen, S, Terbuch, A, Posch, F, Bauernhofer, T, Jost, PJ, Partl, R, Stranzl-Lawatsch, H, Baciarello, G, Fizazi, K, Giannatempo, P, Verzoni, E, Sweeney, C, Ravi, P, Tran, B, Basso, U, White, J, Vincenzi, B, Oing, C, Cutuli, HJ, Dieckmann, KP, Gamulin, M, Chovanec, M, Fankhauser, CD, Heidenreich, A, Mohamad, O, Thibault, C, Fischer, S, and Gillessen, S more...

Abstract

PURPOSE: Radiation therapy is a possible treatment strategy for patients with testicular seminoma after orchiectomy in clinical stage I or II disease. Little is known about the outcome of patients who experience a relapse after radiation therapy. METHODS AND MATERIALS: Data from 61 patients who relapsed after adjuvant or curative radiation therapy from 17 centers in 11 countries were collected and retrospectively analyzed. Primary outcomes were disease-free and overall survival. Secondary outcomes were time to relapse, stage at relapse, treatment for relapse, and rate of febrile neutropenia during chemotherapy for relapse. RESULTS: With a median follow-up of 9.9 years (95% confidence interval [CI], 7.5-10.9), we found a 5-year disease-free survival of 90% (95% CI, 79-95) and a 5-year overall survival of 98% (95% CI, 89-100). Sixty-six percent of patients had stage III disease at time of relapse and 93% of patients fell into the good prognosis group per the International Germ Cell Cancer Collaborative Group classification. The median time to relapse after radiation therapy was 15.6 months (95% CI, 12-23). Twenty-two (36%) patients relapsed more than 2 years after radiation therapy and 7 (11.5%) patients relapsed more than 5 years after radiation therapy. One-third of relapses was detected owing to patients' symptoms, whereas two-thirds of relapses were detected during routine follow-up. The majority (93%) of cases were treated with cisplatin-based chemotherapy. The rate of febrile neutropenia during chemotherapy was 35%. Five patients experienced a second relapse. At last follow-up, 55 patients (90%) were alive without disease. Only 1 patient died owing to disease progression. CONCLUSIONS: Cisplatin-based chemotherapy for patients with seminoma who have relapsed after treatment with radiation therapy alone leads to excellent outcomes. Patients and physicians should be aware of possible late relapses after radiation therapy. more...

Published
2022

22. A0822 - Does multiparametric (mp) MRI and MRI-informed biopsy improve risk allocation of men at inclusion in active surveillance for low-risk prostatic cancer? Results of per-protocol population of the prospective single institution SPRINT trial

Author

Marenghi, C., Badenchini, F., Rancati, T., Avuzzi, B., Messina, A., Casale, A., Catanzaro, M.A., Claps, M., Casbarra, A., Noris Chiorda, B., Guadalupi, V., Stellato, M., Nazzani, S., Stagni, S., Cattaneo, L., Macchi, A., Villa, S., Torelli, T., Verzoni, E., Tesone, A., Procopio, G., and Nicolai, N. more...

Published
2024
Full Text
View/download PDF

23. A0821 - Real world data of active surveillance protocols in low-risk prostate cancer. Intensity of follow-up may be reduced according to a 14 years’ experience

Author

Marenghi, C., Badenchini, F., Avuzzi, B., Catanzaro, M.A., Claps, M., Casbarra, A., Noris Chiorda, B., Guadalupi, V., Stellato, M., Nazzani, S., Stagn, S., Cattaneo, L., Casale, A., Messina, A., Villa, S., Macchi, A., Torelli, T., Tesone, A., Verzoni, E., Procopio, G., Rancati, T., and Nicolai, N. more...

Published
2024
Full Text
View/download PDF

25. 1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment

Author

Miceli, R., primary, Eriksson, H., additional, Eustace, A.J., additional, Lo Russo, G., additional, Ballot, J., additional, Bergamini, C., additional, Bjaanæs, M.M., additional, Corti, F., additional, De Cecco, L., additional, Frisardi, L., additional, Giannatempo, P., additional, Verzoni, E., additional, Helland, A., additional, and Crown, J.P., additional more...

Published
2021
Full Text
View/download PDF

26. 695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma

Author

Del Re, M., primary, Brighi, N., additional, Rizzo, M., additional, Paolieri, F., additional, Rebuzzi, S.E., additional, Beninato, T., additional, Crucitta, S., additional, Mercinelli, C., additional, Gri, N., additional, Puglisi, S., additional, Verzoni, E., additional, Bleve, S., additional, Cucchiara, F., additional, Procopio, G., additional, Fornarini, G., additional, Galli, L., additional, Porta, C.G., additional, De Giorgi, U., additional, and Danesi, R., additional more...

Published
2021
Full Text
View/download PDF

27. 654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)

Author

Procopio, G., primary, Claps, M., additional, Sepe, P., additional, Buti, S., additional, de Cecco, L., additional, Devecchi, A., additional, Dugo, M., additional, Gargiuli, C., additional, Guadalupi, V., additional, Ottini, A., additional, Sensi, M., additional, De Braud, F., additional, and Verzoni, E., additional more...

Published
2021
Full Text
View/download PDF

28. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

Author

Grimm, M-O., primary, Oya, M., additional, Choueiri, T.K., additional, Schmidinger, M., additional, Quinn, D.I., additional, Gravis Mescam, G., additional, Verzoni, E., additional, Van den Eertwegh, A.J.M., additional, di Pietro, A., additional, Mariani, M., additional, Wang, J., additional, Thomaidou, D., additional, and Albiges, L., additional more...

Published
2021
Full Text
View/download PDF

29. 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic

Author

Claps, M., primary, Jachetti, E., additional, Ferri, R., additional, Badenchini, F., additional, Verzoni, E., additional, Montone, R., additional, Sepe, P., additional, Guadalupi, V., additional, Ottini, A., additional, Baciarello, G., additional, Valdagni, R., additional, Colombo, M.P., additional, de Braud, F., additional, and Procopio, G., additional more...

Published
2021
Full Text
View/download PDF

31. LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

Author

Albiges, L., Rini, B.I., Peltola, K., De Velasco Oria, G.A., Burotto, M., Suarez Rodriguez, C., Ghatalia, P., Iacovelli, R., Lam, E.T., Verzoni, E., Gumus, M., Stadler, W.M., Kollmannsberger, C.K., Melichar, B., Venugopal, B., Wang, A., Perini, R., Vickery, D., Powles, T.B., and Choueiri, T.K. more...

Published
2023
Full Text
View/download PDF

32. 1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)

Author

Verzoni, E., Procopio, G., Bottiglieri, A., Stellato, M., Rametta, A., Zucali, P.A., Perrucci, B., G. fornarini, Buti, S., Maruzzo, M., Cova, A., Squarcina, P., Lalli, L., Mereu, A., Cerioli, N., Agnelli, L., Todoerti, K., Busico, A., Rivoltini, L., and Huber, V. more...

Published
2023
Full Text
View/download PDF

33. 1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

Author

Iacovelli, R., Ciccarese, C., Bersanelli, M., Zucali, P.A., Fantinel, E., Bimbatti, D., Verzoni, E., Accettura, C., Bonomi, L., Buttigliero, C., G. fornarini, Pipitone, S., Atzori, F., Masini, C., Massari, F., Primi, F., Buti, S., Perrino, M.R.A., Pafumi, S., and Tortora, G. more...

Published
2023
Full Text
View/download PDF

34. 2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial

Author

Giannatempo, P., Bottiglieri, A., Guadalupi, V., Marandino, L., Raggi, D., Stellato, M., Rametta, A., Baciarello, G., Sepe, P., Claps, M., Buti, S., Pipitone, S., Iacovelli, R., Calareso, G., Alessi, A., Cattaneo, L., Verzoni, E., Ortega, C., Procopio, G., and Necchi, A. more...

Published
2023
Full Text
View/download PDF

36. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Author

Mennitto, A., primary, Verzoni, E., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V. E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Claps, M., additional, Guadalupi, V., additional, Sepe, P., additional, Cappelletti, V., additional, de Braud, F. G., additional, and Procopio, G., additional more...

Published
2021
Full Text
View/download PDF

37. 739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)

Author

Stellato, M., primary, Santini, D., additional, Verzoni, E., additional, De Giorgi, U., additional, Casadei, C., additional, Buti, S., additional, Maruzzo, M., additional, Murianni, V., additional, Sbrana, A., additional, Di Lorenzo, G., additional, Anesi, C., additional, Sorarù, M., additional, Naglieri, E., additional, De Vivo, R., additional, Vignani, F., additional, Grillone, F., additional, Mucciarini, C., additional, Roviello, G., additional, Pignata, S., additional, and Procopio, G., additional more...

Published
2020
Full Text
View/download PDF

38. LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study

Author

Bersanelli, M., primary, Giannarelli, D., additional, Verzoni, E., additional, Buti, S., additional, De Giorgi, U., additional, Clemente, A., additional, Filetti, M., additional, Di Napoli, M., additional, Calvetti, L., additional, Ermacora, P., additional, Catino, A.M., additional, Guaitoli, G., additional, Bonomo, P., additional, Mazzoni, F., additional, Veccia, A., additional, Grosso, F., additional, Maruzzo, M., additional, Rossi, E., additional, Grossi, F., additional, and Procopio, G., additional more...

Published
2020
Full Text
View/download PDF

39. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

Author

Procopio, G., primary, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Passalacqua, R., additional, Mennitto, A., additional, Sepe, P., additional, Martinetti, A., additional, Montone, R., additional, Apollonio, G., additional, Guadalupi, V., additional, Verzoni, E., additional, and Claps, M., additional more...

Published
2020
Full Text
View/download PDF

42. Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study

Author

Procopio, G., primary, Apollonio, G., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Ratta, R., additional, Raimondi, A., additional, Claps, M., additional, Martinetti, A., additional, Capitanio, U., additional, De Braud, F.G., additional, Cappelletti, V., additional, and Verzoni, E., additional more...

Published
2019
Full Text
View/download PDF

44. Do number of biopsies and PSA doubling time at 3 and 5 years in active surveillance protocols associate with upgrading reclassification?

Author

Nicolai, N., primary, Badenchini, F., additional, Marenghi, C., additional, Rancati, T., additional, Magnani, T., additional, Villa, S., additional, Avuzzi, B., additional, Morlino, S., additional, Noris Chiorda, B., additional, Catanzaro, M.A., additional, Tesone, A., additional, Stagni, S., additional, Torelli, T., additional, Macchi, A., additional, Salvioni, R., additional, Colecchia, M., additional, Procopio, G., additional, Verzoni, E., additional, Massa, S., additional, and Valdagni, R., additional more...

Published
2019
Full Text
View/download PDF

46. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts)

Author

Verzoni, E., primary, Ferro, S., additional, Procopio, G., additional, Cova, A., additional, Ratta, R., additional, Raimondi, A., additional, Sepe, P., additional, Squarcina, P., additional, Lalli, L., additional, Huber, V., additional, Rinchai, D., additional, Bedognetti, D., additional, and Rivoltini, L., additional more...

Published
2018
Full Text
View/download PDF

47. Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?

Author

Farè, E., primary, Sdao, S., additional, Damian, S., additional, Cresta, S., additional, Del Vecchio, M., additional, Di Bartolomeo, M., additional, Di Guardo, L.A., additional, Duca, M., additional, Indini, A., additional, Necchi, A., additional, Niger, M., additional, Prisciandaro, M., additional, Procopio, G., additional, Raggi, D., additional, Verzoni, E., additional, Pruneri, G., additional, Di Nicola, M., additional, and de Braud, F.G.M., additional more...

Published
2018
Full Text
View/download PDF

48. Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)

Author

Verzoni, E., primary, Cartenì, G., additional, Cortesi, E., additional, Roila, F., additional, Vitale, M.G., additional, Buti, S., additional, Pignata, S., additional, Cognetti, F., additional, Giustini, L., additional, Damiani, A., additional, Turci, D., additional, Sternberg, C.N., additional, Porta, C., additional, Carrozza, F., additional, Tortora, G., additional, Tassinari, D., additional, Passalacqua, R., additional, Pazzola, A., additional, Surico, G., additional, and Procopio, G., additional more...

Published
2018
Full Text
View/download PDF

49. Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Author

Procopio, G., primary, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Passalacqua, R., additional, Ratta, R., additional, de Braud, F.G.M., additional, Cappelletti, V., additional, and Verzoni, E., additional more...

Published
2018
Full Text
View/download PDF

50. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Author

Bersanelli, M, Giannarelli, D, Castrignanò, P, Fornarini, G, Panni, S, Mazzoni, F, Tiseo, M, Rossetti, S, Gambale, E, Rossi, Ernesto, Papa, A, Cortellini, A, Lolli, C, Ratta, R, Michiara, M, Milella, M, De Luca, E, Sorarù, M, Mucciarini, C, Atzori, F, Banna, Gl, La Torre, L, Vitale, Mg, Massari, F, Rebuzzi, Se, Facchini, G, Schinzari, Giovanni, Tomao, S, Bui, S, Vaccaro, V, Procopio, G, De Giorgi, U, Santoni, M, Ficorella, C, Sabbatini, R, Maestri, A, Natoli, C, De Tursi, M, Di Maio, M, Rapacchi, E, Pireddu, A, Sava, T, Lipari, H, Comito, F, Verzoni, E, Leonardi, F, Buti, S1, Rossi Ernesto, Schinzari Giovanni (ORCID:0000-0001-6105-7252), Bersanelli, M, Giannarelli, D, Castrignanò, P, Fornarini, G, Panni, S, Mazzoni, F, Tiseo, M, Rossetti, S, Gambale, E, Rossi, Ernesto, Papa, A, Cortellini, A, Lolli, C, Ratta, R, Michiara, M, Milella, M, De Luca, E, Sorarù, M, Mucciarini, C, Atzori, F, Banna, Gl, La Torre, L, Vitale, Mg, Massari, F, Rebuzzi, Se, Facchini, G, Schinzari, Giovanni, Tomao, S, Bui, S, Vaccaro, V, Procopio, G, De Giorgi, U, Santoni, M, Ficorella, C, Sabbatini, R, Maestri, A, Natoli, C, De Tursi, M, Di Maio, M, Rapacchi, E, Pireddu, A, Sava, T, Lipari, H, Comito, F, Verzoni, E, Leonardi, F, Buti, S1, Rossi Ernesto, and Schinzari Giovanni (ORCID:0000-0001-6105-7252) more...

Abstract

AIM: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. METHODS: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. RESULTS: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p < 0.0001. CONCLUSION: Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy. more...

Published
2018